Patents by Inventor Odin Johann Naderer

Odin Johann Naderer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • USES AND METHODS FOR RECURRENT PRIMARY CNS NEOPLASMS
    Publication number: 20240238297
    Abstract: This disclosure relates, at least in part, to a method of treatment. In one embodiment, the method of treatment comprises administering to a subject in need of such treatment at least a first therapeutic agent including ONC-206, 7-benzyl-4-(2,4-difluorobenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, for the treatment of one or more CNS neoplasms.
    Type: Application
    Filed: May 13, 2022
    Publication date: July 18, 2024
    Inventors: Joshua Edward Allen, Jill Christine CHAPPELL, Andrew Kang-Kang LEE, Odin Johann NADERER, Varun Vijay PRABHU, Phiroze Behram SETHNA
  • FORMULATIONS OF BRINCIDOFOVIR
    Publication number: 20230210873
    Abstract: Disclosed are formulations comprising brincidofovir. The formulations can be intravenous formulations. The formulations can be used in cases where a subject experiences gastrointestinal issues in response to oral administration of brincidofovir. The formulations can also be used in cases where oral administration of drug is not possible due to underlying conditions or concern around inadequate oral absorption.
    Type: Application
    Filed: July 25, 2022
    Publication date: July 6, 2023
    Inventors: Mohammed KABIR, Odin Johann NADERER, Irma Marisa GROSSI
  • FORMULATIONS OF BRINCIDOFOVIR
    Publication number: 20200138835
    Abstract: Disclosed are formulations comprising brincidofovir. The formulations can be intravenous formulations. The formulations can be used in cases where a subject experiences gastrointestinal issues in response to oral administration of brincidofovir. The formulations can also be used in cases where oral administration of drug is not possible due to underlying conditions or concern around inadequate oral absorption.
    Type: Application
    Filed: December 20, 2019
    Publication date: May 7, 2020
    Inventors: Mohammed Anowrul KABIR, Odin Johann NADERER, Irma Marisa GROSSI
  • FORMULATIONS OF BRINCIDOFOVIR
    Publication number: 20170368082
    Abstract: Disclosed are formulations comprising brincidofovir. The formulations can be intravenous formulations. The formulations can be used in cases where a subject experiences gastrointestinal issues in response to oral administration of brincidofovir. The formulations can also be used in cases where oral administration of drug is not possible due to underlying conditions or concern around inadequate oral absorption.
    Type: Application
    Filed: June 28, 2017
    Publication date: December 28, 2017
    Inventors: Roy Wendell WARE, Mohammed Anowrul KABIR, Odin Johann Naderer, Irma Marisa GROSSI